Search

Citrus bioflavonoids

Platelet Lysate

Platelet lysate is an acellular compound composed of platelet proteins while also being void of cellular debris, thus making the lysate rich with growth factors.

Trapidil

Trapidil, a platelet-derived growth factor antagonist, was originally developed as a vasodilator and anti-platelet agent and has been used to treat patients with ischemic coronary heart, liver, and kidney disease.

N-methylnicotinamide

N-methylnicotinamide is an experimental drug with no approved indication or marketed formulation.

Mivacurium

Mivacurium is a bisbenzylisoquinolinium based neuromuscular blocker or muscle relaxant. It binds competitively to cholinergic receptors on the motor end-plate to antagonize the action of acetylcholine, resulting in a block of neuromuscul...

L-aminocarnityl-succinyl-leucyl-argininal-diethylacetal

C-101, also called Myodur, is developed for the treatment of Duchenne’s muscular dystrophy (DMD) which is a morbid genetic disease that can lead to death in late adolescence due to accelerated skeletal

Lipegfilgrastim

The average molecular mass of lipegfilgrastim comprises 18,798 Da for [DB00099], 203 Da for GalNAc, 338 Da for glycylsialic acid and approximately 20,000 Da for PEG [L2449]. … It is used as an alternate to [DB00019] for prophylactic use in cancer patients receiving chemotherapy and at risk for developing chemotherapy-induced neutropenia.

Cannabidivarin

It is one of over 100 cannabinoids identified from the Cannabis plant that can modulate the physiological activity of cannabis, or marijuana [A32584]. … their physiological effects through their binding to the cannabinoid-1 (CB1R) and cannabinoid-2 (CB2R) receptors, the investigational cannabinoids with anticonvulsant action mostly use mechanisms that do

Dicoumarol

Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. … In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.

Eflapegrastim

[L43135] In September 2022, eflapegrastim was approved by the US FDA as a prophylactic against infection, as manifested by febrile neutropenia, in patients receiving certain myelosuppressive anti-cancer … [A252320] It typically develops during the first cycle of chemotherapy and is associated with an increased risk of morbidity and mortality.